VTUS Key Stats
- Unusual 11 Mid-Day Movers 02/12: (LIVE) (OPTT) (CNVR) Higher; (VTUS) (PGRX) (OXGN) Lower Street Insider 02/12 13:09 ET
- Cantor Fitzgerald Downgrades Ventrus Biosciences (VTUS) to Hold Street Insider 02/12 11:11 ET
- Ventrus Biosciences Announces Results From Second Pivotal Phase 3 Trial of Diltiazem Cream (VEN 307) in Patients With Anal Fissure noodls 02/12 10:30 ET
- William Blair Downgrades Ventrus Biosciences (VTUS) to Market Perform Street Insider 02/12 10:28 ET
- VENTRUS BIOSCIENCES INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Yahoo 02/12 09:11 ET
- Ventrus Phase 3 trial of Diltiazem showed no significant difference to placebo Yahoo 02/12 08:07 ET
- Ventrus Bio (VTUS) Reports No Significant Improvement from Placebo Endpoint in VEN 307 Phase 3 Street Insider 02/12 08:03 ET
- Ventrus Bio (VTUS) halted with news pending Street Insider 02/12 07:58 ET
- 3 Biotech Stocks Under $10 Making Big Moves The Street 02/05 04:04 ET
- Ventrus Biosciences (VTUS) Jumps: Stock Rises 10.9% - Tale of the Tape Zacks 01/23 03:46 ET
VTUS Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Ventrus Biosciences is down 56.31% over the last year vs S&P 500 Total Return up 24.21%, AstraZeneca up 52.30%, and Bell Rose Capital down 0.10%.
Balance Sheet View Statement
Pro Ratings for VTUS
Pro Strategies Featuring VTUS
Did Ventrus Biosciences make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
- Sector: Healthcare
- Industry: Drug Manufacturers - Major
- Headquarters Country: United States
- Headquarters State/Province: New York
- Incorporation Country: United States
- Incorporation State/Province: Delaware
Ventrus Biosciences, Inc. is a development stage specialty pharmaceutical company. The Company is engaged in the late-stage clinical development of gastrointestinal products in areas of unmet need, anal fissures, and fecal incontinence.